library.uns.ac.id digilib.uns.ac.

id

DAFTAR PUSTAKA

1. World Health Organization. Global tuberculosis report 2021. Geneva: World Health
Organization; 2021. p. 1-43.
2. Isbaniah F, Burhan E, Sinaga BYM, Yaniftri DB, Handayani D, Harsini, et al.
Pendahuluan. In: Isbaniah F, Burhan E, editors. Tuberkulosis pedoman diagnosis dan
penatalaksanaan di Indonesia. 2 nd ed. Jakarta: Perhimpunan Dokter Paru Indonesia;
2021. p. 1-14.
3. Ando M, Mori A, Esaki H, Shiraki T, Uemura H, Okazawa M et al. The effect of
pulmonary rehabilitation in patient with post tuberculosis lung disorder. CHEST.
2003; 123(6): 1988-95.
4. Allwood BW, Van Der Zalm MM, Amaral AFS, Byrne A, Datta S, Egere U, et al.
Post-tuberculosis lung health: Perspectives from the First International Symposium.
Int J Tuberc Lung Dis. 2020;24(8):820–8.
5. Allwood BW, Byrne A, Meghji J, Rachow A, Van Der Zalm MM, Schoch OD. Post-
Tuberculosis Lung Disease: Clinical Review of an Under-Recognised Global
Challenge. Respiration. 2021;100(8):751–63.
6. Dudala SS, Venkateswarulu TC, Kancharla SC, Kodali VP, Babu DJ. A review on
importance of bioactive compounds of medicinal plants in treating idiopathic
pulmonary fibrosis (special emphasis on isoquinoline alkaloids). Futur J Pharm Sci.
2021;7(1): 1-21.
7. Shanmugasundaram K, Talwar A, Madan K, Bade G. Pulmonary Functions and
Inflammatory Biomarkers in Post-Pulmonary Tuberculosis Sequelae. Tuberc Respir
Dis. 2022;85(2):175–84.
8. Sabir N, Hussain T, Mangi MH, Zhao D, Zhou X. Matrix metalloproteinases:
70
Expression, regulation and role in the immunopathology of tuberculosis. Cell Prolif.
2019;52(4):1–14.
9. Ravimohan S, Kornfeld H, Weissman D, Bisson GP. Tuberculosis and lung damage:
From epidemiology to pathophysiology. Eur Respir Rev. 2018;27:1-31.
10. Kathamuthu GR, Kumar NP, Moideen K, Nair D. Matrix metalloproteinases and

71
library.uns.ac.id digilib.uns.ac.id
72

tissue inhibitors of metalloproteinases are potential biomarkers of pulmonary and

extra-pulmonary tuberculosis. Front. Immunol. 2020;11(3):1–6.
11. Sathyamoorthy T, Sandhu G, Tezera LB, Thomas R, Singhania A, Woelk CH, et al.
Gender-dependent differences in plasma matrix metalloproteinase-8 elevated in
pulmonary tuberculosis. PLoS One. 2015;10(1):1–15.
12. Lou J, Wang Y, Zhang Z, Qiu W. Activation of MMPs in Macrophages by
Mycobacterium tuberculosis via the miR-223-BMAL1 Signaling Pathway. J Cell
Biochem. 2017;118(12):4804–12.
13. Zubair SM, Ali MG, Irfan M. Post tuberculosis radiological sequelae in patients
treated for pulmonary and pleural tuberculosis at a tertiary center in Pakistan. Monaldi
Arch chest Dis. 2021; 92(1): 1-4.
14. Chawla A. Imaging of Pulmonary Artery. Thorac Imaging. 2019;36(1):235–67.
15. Latif S, Sharyar M, Shafee I, Ali J, Mannan A, Deedar S, et al. Six Minute Walk Test
in People with Tuberculosis Sequelae. Pakistan J Med Heal Sci. 2022;16(3):935–7.
16. Meghji J, Lesosky M, Joekes E, Banda P, Rylance J, Gordon S, et al. Patient outcomes
associated with post-tuberculosis lung damage in Malawi: A prospective cohort
study. Thorax. 2020;75(3):269–78.
17. Isbaniah F, Burhan E, Sinaga BYM, Yaniftri DB, Handayani D, Harsini, et al.
Pendahuluan. In: Isbaniah F, Burhan E, editors. Tuberkulosis pedoman diagnosis dan
penatalaksanaan di Indonesia. 2 nd ed. Jakarta: Perhimpunan Dokter Paru Indonesia;
2021. p. 1-14.
18. Gupta MB, Bagri S, Garg A, Singh DK, Choudhary P, Sahni S. Pulmonary function
in cured pulmonary tuberculosis cases. Indian J Tuberc. 2021;36(1):235–67.
19. World Health Organization. Companion handbook to the WHO guidelines for the
programmatic management of drug-resistant tuberculosis. Geneva: World Health
Organization; 2014. p. 7-9.
20. Procop GW, Church DL, Hall G, Janda M, Koneman W, Woods L, et al.
Mycobacteria. In: Procop GW, Church DL, Hall G, Janda M, Koneman W, Woods
L, et al., editors. Koneman’s Color Atlas and Textbook of Diagnostic Microbiology.
7th ed. Philadelphia: Wolters Kluwer; 2017:1219–68.
library.uns.ac.id digilib.uns.ac.id
73

21. Kementerian Kesehatan Republik Indonesia. Pedoman nasional pengendalian

tuberkulosis. In: Dinihari TN, Siagian V, editors. Pedoman nasional pengendalian
tuberkulosis. Jakarta: Kementerian Kesehatan Republik Indonesia; 2014. p. 1-150.
22. Velayati AA, Farnia P. The species concept. In: Velayati AA, Farnia P, Masucci S,
editors. Atlas of mycobacterium tuberculosis. 1st ed. London: Elsevier; 2017. p. 1–
16
23. Kementerian Kesehatan Republik Indonesia. Peraturan menteri kesehatan republik
Indonesia No 67 tentang penanggulangan tuberkulosis. In: Kementerian Kesehatan
Republik Indonesia, editors. Peraturan menteri kesehatan republik Indonesia No 67
tentang penanggulangan tuberkulosis. Jakarta: Kementerian Kesehatan Republik
Indonesia; 2016. p. 1-163.
24. Riches DW, Martin TR. Overview of innate lung immunity and inflammation. In:
Alper S, Jansen WJ, Walker JM, editors. Lung innate immunity and inflammation;
Methods and protocols. 1st ed. New York: Humana Press; 2018. p. 17–32.
25. Torrelles JB, Schlesinger LS. Integrating lung physiology, immunology, and
tuberculosis. Trends Microbiol. 2017;25(8):688-97.
26. Stamm CE, Collins AC, Shiloh MU. Sensing of Mycobacterium tuberculosis and
consequences to both host and bacillus. Immunol Rev. 2016;264(1):204–19.
27. Rengarajan J, Sia JK, Day CL. Immunopathogenesis of tuberculosis in humans. In:
Mukundan H, Chambers MA, Waters WR, Larsen MH, editors. Tuberculosis, leprosy
and mycobacterial diseases of man and animals: the many host of mycobacteria. 1st
ed. Boston: CAB International; 2015. p. 30–71.
28. Zuiga J, García DT, Mendoza TS, Reyna TS, Granados J, Yunis EJ. Cellular and
humoral mechanisms involved in the control of tuberculosis. Clin Dev Immunol.
2018;4(2):1-18.
29. Sia JK, Rengarajan J. Immunology of mycobacterium tuberculosis infection.
Microbiol spectr. 2019;7(4):1-57.
30. Javan MR, Nezhad AA, Shahraki S, Safa A, Aali H. CrossTalk between the immune
system and tuberculosis pathogenesis; a review with emphasis on the immune based
treatment. Int Basic Sci Med. 2016;1(2):40-7.
library.uns.ac.id digilib.uns.ac.id
74

31. Lerner TR, Borel S, Gutierrez MG. The innate immune response in human
tuberculosis. Cell Microbiol. 2018;17(9):1277-85.
32. Simmons JD, Stein CM, Seshadri C, Campo M, Fortune S, Schurr E, et al.
Mycobacterium tuberculosis infection. 2019; 18(9): 575–89.
33. Liu CH, Liu H, Ge B. Innate immunity in tuberculosis: host defense vs pathogen
evasion. Cell Mol Immunol. 2017;14(12):963–75.
34. Scriba TJ, Coussens AK, Fletcher HA. Human immunology of tuberculosis.
Microbiol Spectr. 2017;5(1):1–24.
35. Garra AO, Redford PS, Mcnab FW, Bloom CI, Wilkinson RJ, Berry MPR. The
immune response in tuberculosis. Annu Rev Immunol. 2013;31(17):475–527.
36. Hilda JN, Das S, Tripathy SP, Hanna LE. Role of neutrophils in tuberculosis: A bird's
eye view. Innate Immun. 2020;26(4):240-7.
37. Muefong CN, Sutherland JS. Neutrophils in tuberculosis associated inflammation and
lung pathology. Front Immunol. 2020;11(3):962-70.
38. Borkute RR, Woelke S, Pei G, Dorhoi A. Neutrophils in tuberculosis: cell biology,
cellular networking and multitasking in host defense. Int J Mol Sci. 2021;22(9):1-24.
39. Golla V, Snow K, Mandalakas AM, Schaaf SH, Preez KD, Hesseling A, et al. The
impact of drug resistance on the risk of tuberculosis infection and disease in child
household contacts: a cross sectional study. BMC Infect Dis. 2017;17(593):1–11.
40. Grandjean L, Gilman RH, Martin L, Soto E, Castro B, Lopez S, et al. Transmission
of Multidrug-Resistant and Drug-Susceptible Tuberculosis within Households : A
Prospective Cohort Study. 2015;362:1–22.
41. Perhimpunan Dokter Paru Indonesia. Pedoman tatalaksana infeksi TB laten. In:
Perhimpunan Dokter Paru Indonesia, editor. Pedoman tatalaksana infeksi TB laten.
Jakarta: Badan Penerbit FKUI; 2016. p. 1-38.
42. Martino M De, Lodi L, Galli L, Chiappini E. Immune response to mycobacterium
tuberculosis: a narrative review. Front Pediatr. 2019;7(350):1–8.
43. Pagan AJ, Ramakrishnan L. Immunity and immunopathology in the tuberculous
granuloma. Cold Spring Harb Perspect Med. 2018;5(9):1-19.
44. Kolloli A, Singh P, Subbian S. Granulomatous response to mycobacterium
library.uns.ac.id digilib.uns.ac.id
75

tuberculosis infection. In: Venketaraman, editor. Understanding the host immune

response against mycobacterium tuberculosis infection. 1st ed. London: Springer
international publishing; 2018. p:41-66.
45. Evans S, Butler JR, Mattila JT, Kirschner DE. Systems biology predicts that fibrosis
in tuberculous granulomas may arise through macrophage-tomyofibroblast
transformation. PLoS Comput Biol. 2020;16(12):1-21.
46. Warsinske HC, DiFazio RM, Linderman JJ, Flynn JL, Kirschner DE. Identifying
mechanisms driving formation of granuloma-associated fibrosis during
mycobacterium tuberculosis infection. J Theor Biol. 2017;429(9):1-17.
47. Bhavanam S, Rayat GR, Keelan M, Kunimoto D, Drews SJ. Understanding the
pathophysiology of the human TB lung granuloma using in vitro granuloma models.
Future Microbiol. 2016;11(8):1073-8.
48. Karakousis PC, Dutty NK, Manabe YC. Clinical features and diagnosis of
tuberculosis primary infection and progressive tuberculosis. In: Grosset JH, Charsson
RE, editors. Handbook of tuberculosis. 1st ed. London: Springer international
publishing; 2017. p:17-34.
49. Burhan E, Soeroto AY. Tuberkulosis Paru. In: Burhan E, Soeroto AY, Isbaniah F,
editors. Pedoman Nasional Pelayanan Kedokteran: Tatalaksana Tuberkulosis. 1st ed.
Jakarta: Kementerian Kesehatan RI; 2021. p.9-38Wynn TA. Integrating mechanisms
of pulmonary fibrosis. J Exp Med. 2011; 208(7): 1339–50.
50. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med. 2017; 208(7):
1339-50.
51. Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med.
2020;383(10):958-68.
52. Brown KK, Martinez FJ, Walsh SLF, et al. The natural history of progressive
fibrosing interstitial lung diseases. Eur Respir J. 2020; 55(5): 1-8.
53. Ravligione MC. Tuberculosis. In: Jameson JL, Kasper DL, Longo DL, Fauci AS,
Hauser SL, Losealzo J, editors. Harrison's principles of internal medicine. 20th ed.
New York: McGraw-Hill Education; 2018. p. 1236-59.46.
54. Hopewell PC, Maida MK, Mason RJ, Ernst JD. Tuberculosis. In: Broaddus VC,
library.uns.ac.id digilib.uns.ac.id
76

Mason RJ, Ersnt JD, Junior TEK, Lazarus SC, Murray JF, et al. Murray & nadels's
textbook of respiratory medicine. 6th ed. Philadelphia: Elsevier Saunders; 2016. p.
593-628.
55. Miggiano R, Rizzi M, Ferraris DM. Mycobacterium tuberculosis pathogenesis,
infection prevention and treatment. Pathogens. 2020;9(5):10–3.
56. Plantier L, Cazes A, Dinh-Xuan AT, Bancal C, Marchand-Adam S, Crestani B.
Physiology of the lung in idiopathic pulmonary fibrosis. Eur Respir Rev. 2018;
27(147): 1-14.
57. Yunus F, Faisal HD. Kapasitas difusi paru. In: Rasmin M, Jusuf A, Taufik, Nawas
MA, Rai IBN, Yunus F, et al, editors. Buku ajar pulmonologi dan kedokteran
respirasi. Buku 1. Jakarta: UI Press. p. 241-9.
58. Graham BL, Steenbruggen I, Barjaktarevic IZ, et al. Standardization of spirometry
2019 update an official American Thoracic Society and European Respiratory Society
technical statement. Am J Respir Crit Care Med. 2019; 200(8): 70-88.
59. Rosyid AN, Marhana IA. Faal paru difusi. J Respirasi. 2018; 4(2): 1-6.
60. Issues S, Test MW, Equipment R, Preparation P. American Thoracic Society ATS
Statement : Guidelines for the Six-Minute Walk Test. 2002;166:111–7.
61. Laksono K, Surya SP. The six minute walk test as a marker of functional capacity in
hypertensive patients. JEKK. 2021; 6(2): 254-60.
62. Hanekom S, Fell BL, Heine M. Six minute walk test protocol variations in low
resource settings: A scoping review. S. Afr. J. Physioter. 2021; 22(12): 1-9.
63. Visca D, Zampogna E, Sotgiu G et al. Pulmonary rehabilitation is effective in patients
with tuberculosis pulmonary sequelae. Eur Respir J. 2019; 53: 1-6.
64. Riyanto BS, Hisyam B, Budiono E, Calmette A, Pasteur I. Hubungan antara Derajat
Sekuele Tuberkulosis dengan Uji Jarak Tempuh Jalan 6 Menit pada Pasien dengan
Sekuele Tuberkulosis Paru Test in Patients with Pulmonary Tuberculosis Sequelae. J
respirologi. 2013;34(3):127–31.
65. Shi X, Guy ES, Barbosa EJM, et al. Pulmonary tuberculosis : role of radiology in
diagnosis and. 2017; (1): 52-72.
66. Lamrani YA, Alami B. Pulmonary tuberculosis sequelae: spectrum radiologic.
library.uns.ac.id digilib.uns.ac.id
77

JMSR. 2018; 2(2): 144-53.

67. Khan R, Malik NI, Razaque A. Imaging of pulmonary post-tuberculosis sequelae.
Pak J Med Sci. 2020;36(1): S75-S82.
68. Menon B, Nima G, Dogra V, Jha S. Evaluation of the radiological sequelae after
treatment completion in new cases of pulmonary, pleural, and mediastinal
tuberculosis. Lung India. 2015;32(3):241–5.
69. Elkington PT, Ugarte-Gil CA, Friedland JS. Matrix metalloproteinases in lung health
and disease: Matrix metalloproteinases in tuberculosis. Eur Respir J. 2011;38(2):456–
64.
70. Zhou X. Matrix metalloproteinases : expression, regulation and role in the
immunopathology of tuberculosis. 2019;(March):1–14.
71. Laronha H, Caldeira J. Structure and Function of Human Matrix Metalloproteinases.
Cells. 2020;9(5).
72. Pardo A, Selman M. MMP-1: The elder of the family. Int J Biochem Cell Biol.
2005;37(2):283–8.
73. Dahlan MS. Statistika untuk kedokteran dan kesehatan. Deskriptif, bivariat, dan
multivariat dilengkapi aplikasi dengan menggunakan SPSS. Jakarta: Salemba
Medika. p. 1-49.
74. Ranzani OT, Rodrigues LC, Bombarda S, Minto CM, Waldman EA, Carvalho CRR.
Long-term survival and cause-specific mortality of patients newly diagnosed with
tuberculosis in São Paulo state, Brazil, 2010–15: a population-based, longitudinal
study. Lancet Infect Dis. 2020;20(1):123–32.
75. Menzies NA, Quaife M, Allwood BW, Byrne AL, Coussens AK, Harries AD, et al.
Lifetime burden of disease due to incident tuberculosis: a global reappraisal including
post-tuberculosis sequelae. Lancet Glob Heal [Internet]. 2021;9(12):e1679–87.
Available from: http://dx.doi.org/10.1016/S2214-109X(21)00367-3
76. Dotulong Jendra F.J, Margareth R. Sapulete GDK. Hubungan faktor risiko umur,
jenis kelamin, dan kepadatan hunian dengan kejadin TB paru di desa wori. J Kedokt
Trop. 2015;1(3):1–10.
77. Matozinhos FP, Velasquez-Melendez G, Tiensoli SD, Moreira AD, Gomes FSL.
library.uns.ac.id digilib.uns.ac.id
78

Factors associated with the incidence of pressure ulcer during hospital stay. Rev da
Esc Enferm. 2017;51:1–7.
78. Okrianti S. Factors Associated With Early Marriage in Deli Serdang, North Sumatera.
2019;555–555.
79. Christine T, Tarigan AP, Ananda FR. Korelasi antara Tingkat Transforming Growth
Factor- β . dengan Fibrosis Paru pada Pasca Tuberkulosis Paru di Medan , Sumatera
Utara – Indonesia. 2019;7(13):2075–8.
80. Yanti Z. Pengaruh Diabetes Melitus Terhadap Keberhasilan. J Berk Epidemiol.
2017;5(Mei 2017):163–73.
81. Sandha LMH, Sari KAK. Tingkat Pengetahuan dan Kategori Persepsi Masyarakat
Terhadap Penyakit Tuberkulosis (TB) di Desa Kecicang Islam Kecamatan Bebandem
Karangasem-Bali. E-Jurnal Med Udayana. 2017;6(12):131–9.
82. Sutanta. Hubungan Antara Tingkat Pendidikan PMO , Jarak Rumah dan Pengetahuan
Pasien TB Paru Dengan Kepatuhan Berobat di BP4. 2014;05(02):163–70.
83. Poliklinik DI, Rsup P, Padang MD. Fakultas Kedokteran Universitas Andalas. 2018;
84. Yen YF, Hu HY, Lee YL, Ku PW, Lin IF, Chu D, et al. Obesity/overweight reduces
the risk of active tuberculosis: A nationwide population-based cohort study in
Taiwan. Int J Obes. 2017;41(6):971–5.
85. Cubilla-Batista I, Ruiz N, Sambrano D, Castillo J, De Quinzada MO, Gasteluiturri B,
et al. Overweight, obesity, and older age favor latent tuberculosis infection among
household contacts in low tuberculosis-incidence settings within Panama. Am J Trop
Med Hyg. 2019;100(5):1141–4.
86. Abdominal P, Exercise S, Penurunan T, Nyeri I. Fakumi medical journal.
2022;2(5):359–67.
87. Wulandari DR, Sugiri YJ. Diabetes Melitus dan Permasalahannya pada Infeksi
Tuberkulosis. 2013;33(2):126–34.
88. Shanmugasundaram K, Talwar A, Madan K, Bade G. Pulmonary Functions and
Inflammatory Biomarkers in Post-Pulmonary Tuberculosis Sequelae. Tuberc Respir
Dis (Seoul). 2022;85(2):175–84.
89. Mancuzo EV, Sulmonett N. treatment of pulmonary tuberculosis. 2021;(July):1–10.
library.uns.ac.id digilib.uns.ac.id
79

90. Nur D, Achadiono W, Retnowulan H, Utami TP. Relationship between the Degrees
of Severity Sequelae after Treatment with Quality of Life in Patients of Pulmonary
Tuberculosis Patients. Acta Interna J Intern Med. 2017;6(1):1–8.
91. Latif S, Sharyar M, Shafee I, Ali J, Mannan A, Deedar S, et al. Six Minute Walk Test
in People with Tuberculosis Sequelae. Pakistan J Med Heal Sci. 2022;16(3):935–7.
92. Di Naso FC, Pereira JS, Schuh SJ, Unis G. Functional evaluation in patients with
pulmonary tuberculosis sequelae. Rev Port Pneumol (English Ed [Internet].
2011;17(5):216–21. Available from: http://dx.doi.org/10.1016/j.rppnen.2011.06.005
93. Shanmugapriya K, Mani AP, Gururaj P, Balakrishnan H. Association between six-
minute walk tests with lung diffusion capacity for carbon monoxide in chronic
respiratory disease: A cross-sectional study. Biomed. 2022;42(4):807–11.
94. Todd JL, Vinisko R, Liu Y, Neely ML, Overton R, Flaherty KR, et al. Circulating
matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with
idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort. BMC
Pulm Med. 2020;20(1):1–12
95. Herrera MT, Guzmán-Beltrán S, Bobadilla K, Santos-Mendoza T, Flores-Valdez
MA, Gutiérrez-González LH, et al. Human Pulmonary Tuberculosis: Understanding
the Immune Response in the Bronchoalveolar System. Biomolecules. 2022;12(8).
96. Fishman JE, Kim GHJ, Kyeong NY, Goldin JG, Glassberg MK. Intravenous stem
cell dose and changes in quantitative lung fibrosis and DLCO in the AETHER trial:
A pilot study. Eur Rev Med Pharmacol Sci. 2019;23(17):7568–72.